Davion Healthcare Plc, a leading medical device manufacturer, has today (13th November 2023) announced the appointments of Sir Eric Peacock as Chairman of the company, Mr Jon Chadwick as Chief Operating Officer and Mr Julian F. Sluyters as a Non-Executive Director.
Sir Eric Peacock is the Chairman of IPro Sport Holdings Ltd (hydration drinks), Buckley Jewellery Ltd, Stevenage Packaging Ltd, Kingfisher Beer Europe Ltd and is the Senior Non-Executive Director of Bango Plc. He has a wide ranging experience of start up’s, turnarounds, financing, acquiring, disposal and floatation with a significant international background having run businesses in Australia, New Zealand, South Africa, France and Ireland. He was knighted in 2003 for his services to International Trade and is also Chairman of the charity The Big Cat Sanctuary and the charities Uniqueness and The AB Trust both of which focus on disadvantaged children and young adults.
Mr Jon Chadwick brings nearly three decades of experience in the financial services industry, with a notable shift in focus towards the dynamic fields of Med Tech and Bio Tech since 2019. His journey began in the intricate realm of financial services, where he honed his skills and developed a keen understanding of the industry’s complexities. Over the years, Jon’s professional trajectory evolved organically, aligning with his growing passion for innovation and cutting-edge technologies in the realms of Medical Technology and Biotechnology.
Mr Julian F. Sluyters has had a 40-year career in the financial services industry, initially in public accounting, specializing in banks, asset management firms, and mutual funds. Over the past three decades, he held various leadership roles in asset management firms, including CEO positions in global mutual fund and European fund services companies. He has extensive board experience, having served on over 20 different mutual fund boards in the US and Europe and as a Trustee for five boards. Mr. Sluyters is also an audit committee financial expert and has expertise in private equity and alternative asset classes.
Jack Kaye, Davion’s CEO said “I am delighted to welcome Sir Eric Peacock, Mr Jon Chadwick and Mr Julian Sluyters to the Davion Board. I know they will all make valuable contributions to the ongoing success of the company.”
Davion Healthcare Plc is pleased to announce the appointments of Sir Eric Peacock as Chairman of the company with immediate effect, Mr Jon Chadwick as Chief Operating Officer and Mr Julian F. Sluyters as a Non-Executive Director.
Sir Eric Peacock is the Chairman of multiple companies and was knighted in 2003 for his services to International Trade. Mr Jon Chadwick brings nearly three decades of experience in the financial services industry, with a notable shift in focus towards the dynamic fields of Med Tech and Bio Tech since 2019. Mr Julian F. Sluyters has held various leadership roles in asset management firms, including CEO positions in global mutual fund and European fund services companies.
Jack Kaye, Davion’s CEO said “I am delighted to welcome Sir Eric Peacock, Mr Jon Chadwick and Mr Julian Sluyters to the Davion Board. I know they will all make valuable contributions to the ongoing success of the company.”
Davion Healthcare is committed to delivering exceptional value to its shareholders whilst driving innovation within the medical sector. The company is also preparing for the listing of its ADR’s on the NASDAQ stock exchange early next year.
Munro Forbes, Media Relations Manager at Davion Healthcare, said: “Our mission is to create and manage an environment for the secure development of new medical devices. With a current focus on accessible products available for self-use in the comfort of your own home utilising smart technology interfaces, we are committed to empowering individuals to take control of their health and well-being by providing them with the tools they need to detect potential health issues at an early stage. We just happen to make great medical devices that can make a difference in people’s lives.”
The Directors of the Issuer accept responsibility for the contents of this announcement.
